Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Prevenar 20 to Join National Immunization for Children from October
August 1, 2024
- Japan Aspires to Double Private Investments in Pharma Startups over 5 Years
July 31, 2024
- Japan OKs FY2025 Budget Ceiling, 410 Billion Yen for Social Security Cost Rise
July 31, 2024
- MHLW Council Begins Discussions on Rx-to-OTC Switch of 3 New APIs
July 31, 2024
- MHLW Panel Discusses Ways to Rationalize Ethical Narcotics Distribution
July 30, 2024
- Japan Panel Backs Rx-to-OTC Switch of 4 PPIs
July 30, 2024
- MHLW Mulls System to Seek Expert Input for Patent Linkage
July 29, 2024
- LDP Members Fret over Easier Access to Abortion Pill Mefeego
July 29, 2024
- Off-Year Revision Debate to Follow Honebuto Policy: MHLW Bureau Chief
July 29, 2024
- MHLW Plans Disposal of COVID-19 Antibody Meds in Government Stock
July 26, 2024
- HeartSheet’s Conditional Approval to Be Withdrawn as Early as August
July 26, 2024
- LDP Policy Panel OKs FY2025 Budget Guidelines, Lower Cap Likely for “Natural Increase”
July 24, 2024
- Health Minister Hopes to Tap US Insights to Foster Japan Ecosystem
July 24, 2024
- MHLW Seeks Input to Gird for Summer Outbreaks, FPMAJ Ready to Ask for Ramp-Up
July 23, 2024
- Japan’s Fall-Winter COVID Vaccinations Likely to Start from October
July 23, 2024
- MHLW Panel to Review Takeda’s Fruzaqla on Aug. 2; Truvada, Keytruda, Prevenar 20 on Roster Too
July 22, 2024
- MHLW Sets Exceptions to All-Case PMS through Revised Q&A
July 22, 2024
- Japan Panel Says No to Full Approval of HeartSheet, Clears Breyanzi’s Broader Label
July 22, 2024
- Japan Panel Discusses Details of NIP for Shingles Jabs, OKs Inclusion of Prevenar 20
July 19, 2024
- Lilly’s Alzheimer’s Med Up for Health Ministry Panel Review on August 1
July 19, 2024
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…